Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Filings indexed 498 across all filing types
Latest filing 2020-03-02 Regulatory Filings
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Board Meeting — Other business matters
Regulatory Filings
2020-03-02 English
Press Release
Regulatory Filings
2020-02-17 English
Press Release
Regulatory Filings
2020-02-15 English
Financial Result Updates
Regulatory Filings
2020-02-15 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a disclosure under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated 14th February 2020. It contains unaudited financial results for the quarter and nine months ended 31st December 2019, including detailed financial tables and notes. It also includes a Limited Review Report by the statutory auditors, which is typical for interim financial results. The presence of quarterly and nine-month financial data, along with auditor's limited review, indicates this is an Interim / Quarterly Report. The document is about 15,000 characters, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2020
2020-02-14 English
Press Release
Regulatory Filings
2020-02-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.